Shares of Australia’s Tetratherix (TTX) climbed as much as 10.1% to A$4.24, marking their highest level since mid-November. If current trends continue, the stock is set for its strongest session in six weeks.

The regenerative biomaterials company said its joint venture partner BioOptix has entered into an agreement with Alcon Research. Under the deal, Alcon Research will provide funding to accelerate the commercialization of products developed from Tetratherix’s Tetramatrix platform technology.

The Tetramatrix platform is a biomaterials technology designed to create implantable products for a variety of clinical applications, according to the company’s website.

Tetratherix shares have gained nearly 25% since the company listed on June 30, reflecting growing investor confidence in its platform and strategic partnerships.